Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

Related Content:

State of the Science Summit on Genitourinary CancersOncLive TVProstate Cancer
Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL
Dr Battiwalla on the Expanding Use of Bispecific Antibodies in NHL
Dr Gluz on Survival Outcomes With De-Escalated Neoadjuvant Regimens in HR+/HER2+ Early Breast Cancerer